CCRM Australia Welcomes Professor Alice Pébay AM as Chief Scientific Officer, Strengthening Leadership in Australian Regenerative Medicine
2nd October 2023
CCRM Australia is thrilled to announce the appointment of Professor Alice Pébay AM as Chief Scientific Officer (CSO). Prof. Pébay's outstanding achievements and leadership within the Australian stem cell and regenerative medicine academic community make her the ideal candidate for this crucial role. CCRM Australia eagerly anticipates the wealth of knowledge and expertise she brings to further advance regenerative medicine in the country and beyond.
Prof. Pébay is a distinguished researcher and innovator whose pioneering work in stem cell biology and ocular regenerative medicine has garnered international recognition. Her research interests encompass pluripotent stem cell differentiation, modelling retinal diseases, and developing therapies for degenerative ocular disorders. Prof. Pébay's contributions have not only pushed the boundaries of scientific discovery but also offer hope for patients seeking life-changing regenerative treatments.
In addition to her research, Prof. Pébay has demonstrated exemplary leadership, fostering collaborations among scientists, clinicians, and industry stakeholders. Her passion for driving progress in regenerative medicine aligns seamlessly with CCRM Australia's objectives to work closely with the local regenerative medicine community and build a thriving ecosystem of innovation.
Commenting on Prof. Pébay's appointment, Silvio Tiziani, CEO of CCRM Australia, expressed enthusiasm, stating, "We are delighted to welcome Prof Alice Pébay as our Chief Scientific Officer. Her appointment underscores CCRM Australia's commitment to fostering excellence in regenerative medicine research and development. Prof. Pébay's expertise will be pivotal in advancing our mission to collaborate with Australian academic colleagues, identify opportunities, and propel the regenerative medicine sector to its full potential."
Prof. Pébay's tenure as CSO will commence on October 1st 2023, marking a significant milestone in CCRM Australia's pursuit of transformative therapies and medical breakthroughs. Importantly, her new role at CCRM Australia will complement her ongoing research program and her collaborations with research and other partners, ensuring continuity in her groundbreaking work.
Prof. Pébay expressed her enthusiasm about joining CCRM Australia, saying, "I am honoured and excited to assume the role of Chief Scientific Officer at CCRM Australia. I look forward to collaborating with my esteemed colleagues and industry partners to drive innovation, create opportunities at an international level through collaborations with other CCRM hubs, and unlock the full potential of regenerative medicine in Australia.
CCRM Australia is eager to witness the impact of Prof. Alice Pébay's leadership in advancing regenerative medicine and propelling the sector's growth in Australia and globally.
About CCRM Australia
CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia's focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry. CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate from CCRM. As a member of the Global CCRM network, CCRM Australia is a partner to a leading-edge industry consortium.
For more information, please contact Silvio Tiziani: m: +61 (0)4 1853 6209
e: silvio.tiziani@ccrmaustralia.com.au